Thromboembolic and cardiovascular risk in rheumatoid arthritis: Role of the haemostatic system

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 954-957

  Van Den Oever, I A M ^a   Sattar, N ^b   Nurmohamed, M T ^a,c  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; CD63 ANTIGEN; CELL ADHESION MOLECULE; CORTICOSTEROID; CYTOKINE; D DIMER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRINOGEN; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; BLOOD CLOTTING; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CYTOKINE RELEASE; ENDOTHELIAL DYSFUNCTION; FIBRIN DEPOSITION; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE FUNCTION; THROMBOEMBOLISM;

AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASE; INFLAMMATION; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; CYTOKINES; HEMOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84899914899     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204767     Document Type: Review

References (31)

1. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121:S9-14.
2. Goldhaber SZ, Visani L, De RM. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353: 1386-9. (Pubitemid 29192409)
3. Chung WS, Peng CL, Lin CL, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis Published Online First: 13 August 2013 doi:10.1136/ annrheumdis.2013. 203380
4. Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011;9:1.
5. Bacani AK, Gabriel SE, Crowson CS, et al. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum 2012;64: 53-61.
6. Zoller B, Li X, Sundquist J, et al. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis 2012;2: 171-83.
7. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148: 209-14. (Pubitemid 30064452)
8. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109: 2698-704. (Pubitemid 38737913)
9. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357: 2482-94.
10. Puddu P, Puddu GM, Cravero E, et al. The involvement of circulating microparticles in inflammation, coagulation and cardiovascular diseases. Can J Cardiol 2010;26: 140-5.
11. Cirillo P, Golino P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation 1. Cardiovasc Res 2005;68: 47-55. (Pubitemid 41253555)
12. Santos MJ, Carmona-Fernandes D, Canhao H, et al. Early vascular alterations in SLE and RA patients-a step towards understanding the associated cardiovascular risk. PLoS One 2012;7:e44668.
13. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001;40: 640-4.
14. McLaren M, Alkaabi J, Connacher M, et al. Activated factor XII in rheumatoid arthritis. Rheumatol Int 2002;22: 182-4. (Pubitemid 35025077)
15. Peters MJ, Nurmohamed MT, van Eyk I, et al. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis 2009;68: 1232-3.
16. Rooney T, Scherzer R, Shigenaga JK, et al. Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. Rheumatology (Oxford) 2011;50: 1458-65.
17. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993;12: 318-24. (Pubitemid 23306865)
18. Juhan-Vague I, Pyke SD, Alessi MC, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94: 2057-263.
19. van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991;174: 729-32.
20. Esmon CT. Coagulation inhibitors in inflammation. Biochem Soc Trans 2005;33: 401-5. (Pubitemid 40604381)
21. Wallberg-Jonsson S, Cederfelt M, Rantapaa DS. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study. J Rheumatol 2000;27: 71-5. (Pubitemid 30058631)
22. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, et al. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol Int 2011;31: 153-64.
23. Mameli A, Barcellona D, Marongiu F. Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol 2009;27: 846-55.
24. Schmidt M, Christiansen CF, Horvath-Puho E, et al. Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost 2011;9: 1326-33.
25. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol 2013;9:30.
26. van Zaane B, Nur E, Squizzato A, et al. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost 2010;8: 2483-93.
27. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359: 1173-7. (Pubitemid 34304256)
28. van Halm V, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
29. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005;94: 362-5. (Pubitemid 41122491)
30. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 2008;31: 175-9.
31. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis Published online First: 24 December 2013 doi:10.1136/annrheumdis-2013-204345